The combination of bortezomib, lenalidomide, and dexamethasone resulted in a partial response or better in more than 60% of patients with relapsed or refractory multiple myeloma, according to results of a phase II trial.
Single patients with soft-tissue sarcoma of the extremities had worse overall survival and were less likely to undergo several important treatment options compared with their married counterparts, according to results of a recent study.
Results of a large meta-analysis indicated that treatment with lenalidomide for newly diagnosed multiple myeloma was associated with an increased risk for developing secondary hematologic malignancies.
The anti-programmed death 1 (PD-1) drug nivolumab may increase overall survival in patients with advanced melanoma with a safe and acceptable long-term safety profile, according to the results of a recent study.
The results of a retrospective study indicated that patients with metastatic GIST who are able to achieve complete macroscopic surgical resection of their disease may be able to achieve long-term survival.